Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | HCA7; HCA 7 |
| Species | Human |
| Cat.No | ABC-TC506S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Colon |
| Storage | Liquid Nitrogen |
| Product Type | Human Colon Cancer Cell Lines |
HCA-7 is a human colorectal adenocarcinoma cell line derived from a 58-year-old female patient with moderately differentiated mucinous carcinoma of the colon. This adherent cell line exhibits epithelial-like morphology and forms polarized monolayers in culture, closely resembling the morphology and functional characteristics of colonic epithelium. A unique feature of HCA-7 is its ability to develop polarized epithelial layers. The cell line expresses high levels of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1), enzymes involved in prostaglandin biosynthesis and inflammation. HCA-7 demonstrates strong tumorigenicity in xenograft models, forming tumors when inoculated subcutaneously into nude mice. It is widely used in studies focused on colon cancer progression, drug resistance, and anticancer therapeutic screening.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The HCA-7 cell line serves as a for studying colorectal cancer biology, particularly in understanding the role of COX-2 in tumorigenesis and inflammation. It is also widely used in research on transepithelial transport, epithelial cell polarity, and the regulation of barrier function by hormones and other factors. Due to the unique Cox-2 expression and its ability to form polarized epithelial layers, HCA-7 is an ideal platform for evaluating the molecular mechanisms underlying colorectal carcinogenesis and testing potential therapeutic interventions targeting COX-2 pathways.
